Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately,
there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by
induction of atovaquone metabolism.
For travelling HIV patients, the clinical consequences of these possible drug drug
interactions are serious, since a diminished exposure to the anti-malarial drug will result
in suboptimal prophylaxis of malaria and potential development of drug resistant strains of
The purpose of this study is to find out if HIV patients using HAART regimes with either
lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels
than healthy volunteers after a single dose of atovaquone/proguanil.
Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Assistance Publique - Hôpitaux de Paris
Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated
malaria in France, according to the French consensus Conference revised in 2007 on the
treatment of imported malaria.
The aim of the study is to compare both tolerance and efficacy of Malarone® and Riamet® in
the treatment of uncomplicated imported malaria and to determine clinical and
parasitological predictive factors associated with a less effectiveness. It's a
multicentric, randomised study in adults with uncomplicated malaria. Treatment will be
administered for 3 days, and patients will be followed for 28 days, to evaluate the
therapeutic evolution. 640 patients will be included among 15 centres.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.